150 related articles for article (PubMed ID: 18386114)
21. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
22. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
23. Cytoplasmic/nuclear localization of tuberin in different cell lines.
Rosner M; Hengstschläger M
Amino Acids; 2007 Nov; 33(4):575-9. PubMed ID: 17458623
[TBL] [Abstract][Full Text] [Related]
24. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
Robb VA; Astrinidis A; Henske EP
Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
[TBL] [Abstract][Full Text] [Related]
25. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2.
Rosner M; Hengstschläger M
J Biol Chem; 2004 Nov; 279(47):48707-15. PubMed ID: 15355997
[TBL] [Abstract][Full Text] [Related]
26. Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin.
Lesma E; Ancona S; Orpianesi E; Grande V; Di Giulio AM; Gorio A
J Pharmacol Exp Ther; 2013 May; 345(2):180-8. PubMed ID: 23426956
[TBL] [Abstract][Full Text] [Related]
27. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.
Rosner M; Hanneder M; Siegel N; Valli A; Hengstschläger M
Mutat Res; 2008; 658(3):234-46. PubMed ID: 18291711
[TBL] [Abstract][Full Text] [Related]
28. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
29. Tuberin activates the proapoptotic molecule BAD.
Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
[TBL] [Abstract][Full Text] [Related]
30. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
Miloloza A; Kubista M; Rosner M; Hengstschläger M
J Neuropathol Exp Neurol; 2002 Feb; 61(2):154-63. PubMed ID: 11853018
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly.
Aronica E; Boer K; Baybis M; Yu J; Crino P
Acta Neuropathol; 2007 Sep; 114(3):287-93. PubMed ID: 17483958
[TBL] [Abstract][Full Text] [Related]
32. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
[TBL] [Abstract][Full Text] [Related]
33. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition.
Shiono M; Kobayashi T; Takahashi R; Sun G; Abe M; Zhang D; Wang L; Piao X; Takagi Y; Mineki R; Taka H; Tada N; Sonobe S; Momose S; Ueda M; Hino O
Oncogene; 2008 Nov; 27(52):6690-7. PubMed ID: 18695678
[TBL] [Abstract][Full Text] [Related]
34. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.
Zacharek SJ; Xiong Y; Shumway SD
Cancer Res; 2005 Dec; 65(24):11354-60. PubMed ID: 16357142
[TBL] [Abstract][Full Text] [Related]
35. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
37. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
38. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
39. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.
Jozwiak J; Jozwiak S; Grzela T; Lazarczyk M
Neuromolecular Med; 2005; 7(4):287-96. PubMed ID: 16391386
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
